Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study

Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study

IntroductionPyrotinib plus capecitabine has been approved in China for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). Meanwhile, vinorelbine is another important chemotherapy option for MBC available in oral and intravenous forms. Thus, pyrotinib plus vinore...

Full description

Bibliographic Details
Main Authors: Yi Li, Yixuan Qiu, Huihui Li, Ting Luo, Wei Li, Hong Wang, Bin Shao, Biyun Wang, Rui Ge
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Oncology
Subjects:
human epidermal growth factor receptor 2 positive
metastatic breast cancer
pyrotinib
vinorelbine
tyrosine kinase inhibitor
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.664429/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.664429/full

Similar Items